Cedric Hermans: New HAVEN 6 Publication Highlights Emicizumab Outcomes in Mild and Moderate Haemophilia A
Cedric Hermans, Head of Haemophilia Centre at the Saint-Luc University Hospital, Brussels, shared a post on LinkedIn about recent article he and his colleauges co-authored, published in Therapeutic Advances in Hematology, adding:
“‘Mild’ describes a factor level – not always the bleeding burden.
Our new HAVEN 6 publication reports long-term emicizumab outcomes in 72 people with mild or moderate haemophilia A without inhibitors who warranted prophylaxis.
At approximately 3 years’ median follow-up, the annualised treated bleed rate was 1.0, with maintained therapeutic exposure and unchanged coagulation safety biomarkers. Two thromboembolic events were reported.
Look beyond FVIII levels.
Personalise protection.”
Title: Emicizumab long-term outcomes and coagulation biomarkers in mild or moderate hemophilia A without inhibitors (HAVEN 6)
Authors: Cedric Hermans, Víctor Jiménez-Yuste, Giuliana Ventriglia, Anna Kiialainen, Laurent Frenzel, Olivier Catalani, Jerzy Windyga, Johannes Oldenburg, Christophe Schmitt, Amy D. Shapiro, Johnny Mahlangu, Michaela Lehle, Steven W. Pipe
More posts featuring Cedric Hermans on Hemostasis Today.
-
Nov 5, 2026, 19:08Ruchi Punamia: The Journey from Research to First Published Book Chapter on Single Donor Platelets
-
Nov 5, 2026, 18:57Maria Luszczyn: Does Blood Transfusion Really Worsen Long-Term Survival after CABG or is Preoperative Anemia the Main Driver?
-
Nov 5, 2026, 18:20Jessica Vega: How Listening to Patient Experience Reframes Warm Autoimmune Hemolytic Anemia Care
-
Nov 5, 2026, 18:15Paresh P Kulkarni: Frontiers in Immunology Launches Call for Papers on Innate Immune Mechanisms and Biomarkers in APS
-
Nov 5, 2026, 18:08Perrine Henry: Iliac Venous Thrombus Identified as Rare Cause of Hindlimb Lameness in Dog with Primary Erythrocytosis
-
Nov 5, 2026, 18:02Kellie Machlus: Bone Marrow Megakaryocytes Present Antigens and Regulate T Cells
-
Nov 5, 2026, 14:42Matteo Foschi: ASPERA-R Reveals the Challenges of Anticoagulation Resumption After Hemorrhagic Transformation
-
Nov 5, 2026, 14:30Khaled Musallam: Assessing the State of Thalassaemia and Sickle Cell Disease Care Across Europe
-
Nov 5, 2026, 14:17Joshua Muia: The Evolution of ADAMTS13 Research